Equity Analyst, Event-driven, Quiddity Advisors

Janaghan Jeyakumar, CFA

Equity Analyst with experience in fundamental and event-driven research in Frontier and Emerging markets. 

On Smartkarma, I mainly publish insights on special situations such as mergers & acquisitions, index rebalance events, equity offerings, buybacks, and other corporate restructuring events mainly in the Asia-Pacific and European equity markets.

Equity Analyst, Event-driven

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

Biofermin Pharmaceutical Co / Event-Driven

On 14th May, Pharmaceutical company <a href="https://www.smartkarma.com/entities/biofermin-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:20533:1" rel="noopener">Biofermin Pharmaceutical Co (4517 JP)</a> ("Biofermin") announced they had agreed to merge with their parent <a href="https://www.smartkarma.com/entities/taisho-pharmaceutical-holdin" target="_blank" data-smartkarma-citation="entities:3774:1" rel="noopener">Taisho Pharmaceutical Holdin (4581 JP)</a> ("Taisho") which will result in Biofermin getting delisted from the Tokyo Stock Exchange. Biofermin shareholders will receive 0.5 Taisho shares per Biofermin share.The Biofermin shareholder meeting for approving the Deal is expected to be on 24th June 2021 and the Merger is expected to become effective on 1st August 2021. More below the fold.

On 14th May, Pharmaceutical company Biofermin Pharmaceutical Co (4517 JP) ("Biofermin") announced they had agreed to merge with their parent Taisho Pharmaceutical Holdin (4581 JP) ("Taisho") which will result in Biofermin getting delisted from the Tokyo Stock Exchange. Biofermin shareholders will receive 0.5 Taisho shares per Biofermin share.The Biofermin shareholder meeting for approving the Deal is expected to be on 24th June 2021 and the Merger is expected to become effective on 1st August 2021. More below the fold.

Biofermin (4517 JP) - Taisho (4581 JP): Merger Is a Done Deal